Compare APOG & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APOG | SPRY |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.1M | 788.5M |
| IPO Year | 1994 | 2020 |
| Metric | APOG | SPRY |
|---|---|---|
| Price | $37.64 | $8.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $47.00 | $40.00 |
| AVG Volume (30 Days) | 149.7K | ★ 1.8M |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $1,404,733,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $2.07 | $81.64 |
| P/E Ratio | $15.31 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $30.75 | $6.66 |
| 52 Week High | $46.14 | $18.63 |
| Indicator | APOG | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 53.78 |
| Support Level | $36.94 | $8.61 |
| Resistance Level | $37.97 | $9.51 |
| Average True Range (ATR) | 1.17 | 0.62 |
| MACD | 0.30 | 0.11 |
| Stochastic Oscillator | 71.53 | 60.93 |
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.